Clinical trial
Immunogenicity and Safety of Combined Vaccine to Prevent Measles, Mumps, Rubella…
NCT00126997 · GlaxoSmithKline, Industry · Completed
Key facts
| NCT number | NCT00126997 |
|---|---|
| Title | Immunogenicity and Safety of Combined Vaccine to Prevent Measles, Mumps, Rubella and Chickenpox Diseases |
| Official title | Blinded, Randomised Study to Assess the Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Live Attenuated Measles-mumps-rubella-varicella Candidate Vaccine When Given to Healthy Children in Their Second Year of Life |
| Lead sponsor | GlaxoSmithKline, Industry |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Mumps, Rubella, Measles, Varicella |
| Intervention type | Biological |
| Interventions | Measles, Mumps, Rubella and Chickenpox (live vaccine) |
| Enrollment | 1,439 |
| Start date | May 1, 2005 |
| Primary completion | Nov 1, 2005 |
| Completion | Nov 1, 2005 |
| First posted | Aug 5, 2005 |
| Last update posted | Sep 21, 2016 |
| Countries | Finland, Germany, Greece, Poland |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: